Enterolactone Reduces Telomerase Activity and The Level of Its Catalytic Subunit in Breast Cancer Cells

(Pages: 37-43)
Davod Ilbeigi, M.Sc, 1Mitra Nourbakhsh, Ph.D, 2,3,*Shahnaz Khaghani, Ph.D, 1,*Nahid Einollahi, Ph.D, 4Nejat Kheiripour, M.Sc, 1Zafar Gholinejad, M.Sc, 1Mohammad Alaee, M.Sc, 1Mostafa Saberian, M.Sc, 4
Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular, Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
Department of Clinical Laboratory Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular, Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
Department of Clinical Laboratory Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Addresses: P.O.Box: 1449614535 Department of Biochemistry School of Medicine Iran University of Medical Sciences Tehran Iran P.O.Box: 1417614418 Department of Biochemistry School of Medicine Tehran University of Medical Sciences Tehran Iran Emails:nourbakhsh.m@iums.ac.ir,khaghani@sina.tums.ac.ir
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ilbeigi Davod, Nourbakhsh Mitra, Khaghani Shahnaz, Einollahi Nahid, Kheiripour Nejat, Gholinejad Zafar, Alaee Mohammad, Saberian Mostafa. Enterolactone Reduces Telomerase Activity and The Level of Its Catalytic Subunit in Breast Cancer Cells. Cell J. 2017; 19(Suppl 1): 37-43.

Abstract

Objective

There is a positive correlation between higher serum phytoestrogen concentrations and lower risk of breast cancer. The activation of telomerase is crucial for the growth of cancer cells; therefore, the aim of this study was to examine the effects of enterolactone (ENL) and enterodiol (END) on this enzyme.

Materials and Methods

In this experimental study, we performed the viability assay to determine the effects of different concentrations of ENL and END on cell viability, and the effective concentrations of these two compounds on cell growth. We used western blot analysis to evaluate human telomerase reverse transcriptase catalytic subunit (hTERT) expression and polymerase chain reaction (PCR)-ELISA based on the telomeric repeat amplification protocol (TRAP) assay for telomerase activity.

Results

Both ENL and END, at 100 μM concentrations, significantly (P<0.05) reduced cell viability. However, only the 100 μM concentration of ENL significantly (P<0.05) decreased hTERT protein levels and telomerase activity. Lower concentrations of ENL did not have any significant effects on telomerase activity and hTERT protein levels.

Conclusion

High concentration of ENL decreased the viability of MCF-7 breast cancer cells and inhibited the expression and activity of telomerase in these cells. Although END could reduce breast cancer cell viability, it did not have any effect on telomerase expression and activity.